SULODEXIDEA PANACEA BIO CHEM RESEARCH PROGRAMME
MENU

MECHANISMS

A network of vascular mechanisms

Sulodexide is best investigated as a vascular-interface modulator rather than reduced to one pharmacological label. Ten interacting research areas make up the map — every node is a link to its explanation.

  1. Antithrombin III

    The fast-moving heparin-like fraction shows affinity for antithrombin III, the endogenous serine-protease inhibitor that regulates coagulation proteases. This is the classical pharmacology of the principal fraction.

  2. Heparin cofactor II

    Dermatan sulfate interacts with heparin cofactor II, a second endogenous serine-protease inhibitor. The two fractions therefore engage two different endogenous anticoagulant systems.

  3. Thrombin regulation

    Through both cofactor pathways, sulodexide participates in thrombin regulation. Regulation is the accurate word: published pharmacology does not describe clotting being completely disabled.

  4. Fibrinolytic balance

    Profibrinolytic properties have been described in the literature, involving the balance of fibrin formation and clearance. Sulodexide must never be portrayed as instantly dissolving established clots.

  5. Endothelial glycocalyx

    Human mechanistic research reported changes in measured glycocalyx dimensions; experimental work reports permeability improvements via glycocalyx remodelling. Evidence exists alongside continuing uncertainty about mechanism, magnitude and clinical meaning.

  6. Nitric oxide

    Isolated vascular-tissue experiments showed endothelium-dependent, nitric-oxide-mediated relaxation. These are vascular-tissue experiments — not proof of a clinical blood-pressure treatment.

  7. Inflammatory signalling

    Endothelial inflammatory signalling intersects with glycocalyx state, permeability and coagulation. Biomarker studies — including convalescent COVID-19 research — measured inflammatory mediators among their endpoints.

  8. Vascular permeability

    Barrier behaviour is a recurring endpoint: transcapillary albumin escape in human mechanistic work, and permeability assays in cell and animal models. Preclinical findings do not translate automatically into human efficacy.

  9. Matrix metalloproteinases

    MMP-2 and MMP-9 participate in extracellular-matrix turnover and venous pathology. Sulodexide research has touched matrix-remodelling pathways relevant to chronic venous disease.

  10. Extracellular matrix

    The extracellular matrix is the structural context in which the endothelium lives. Matrix biology connects sulodexide research to tissue mechanics, remodelling and the wider vascular-repair question.